Detailed Summary of Surfactant Comparisons 
Morbidities 

Study Characteristics 
Surfactants 
Primary Outcome 
Death  #/N (%) 
BPD  #/N (%) 
Severe IVH  #/N (%) 
PDA  #/N (%) 
Bloom et al. [28] 
Prospective Randomized, Doubleblind Multicenter Prophylaxis <29wk,<1250g 
 Calfactant (Surf A) (n=180, 891 ± 221g, 27.1 ± 2.2wk)  Beractant (Surf B) (n=194, 845 ± 205g, 27.1 ± 2.1wk) 
Calfactant group: spent fewer days on ventilator, fewer days on O_{2}, but had more deaths in subgroup <600 g than Beractant group 
Surf A 25/180 (14) Surf B 16/194 (8) 
Surf A 59/180 (33) Surf B 60/194 (31) 
Surf A 9/180 (5) Surf B 10/194 (5) 
Surf A 94/180 (52) Surf B 107/194 (55) 
Bloom et al. [28] 
Prospective Randomized, Doubleblind Multicenter Treatment:
RDS <32 wks, <2 kg 
 Calfactant (Surf A) (n=303, 1162 ± 408g, 29 ± 2.8wk)  Beractant (Surf B) (n=305, 1166 ± 401g, 29 ± 2/9wk) 
Calfactant group: had lower mean airway pressure and FiO_{2} in first 3 days than Beractant group. 
Surf A 55/303 (18) Surf B 52/305 (17) 
Surf A 112/303 (37) Surf B 125/305 (41) 
Surf A 34/303 (11) Surf B 31/305 (10) 
Surf A 114/303 (38) Surf B 118/305 (39) 
Bloom and Clark [29] 
Prospective Randomized, Doubleblind Multicenter Prophylaxis <29 wk, <2 kg 
 Beractant (Surf A) (n=375, 907 ± 275g, 26.6 ± 1.9wk)  Calfactant (Surf B) (n=374, 910 ± 287g, 26.5 ± 2.0wk) 
Calfactant and Beractant groups had similar mortality, IVH, and NEC, but slow enrollment caused early study termination 
Surf A 45/375 (12) Surf B 49/374 (13) 
Surf A 128/375 (34) Surf B 128/374 (34) 
Surf A 18/375 (5) Surf B 11/375 (3) 

Bloom and Clark [29] 
Prospective Randomized, Doubleblind Multicenter Treatment, RDS on Vent, FIO_{2}>40% 
 Beractant (Surf A) (n=673, 1154 ± 402g,28.4 ± 2.8wk)  Calfactant (Surf B) (n=688,1155 ± 408g, 28.4 ± 2.7wk) 
Calfactant and Beractant groups had similar mortality, IVH, and NEC, but slow enrollment caused early study termination 
Surf A 70/673 (10) Surf B 77/688 (11) 
Surf A 205/673 (30) Surf B 210/688 (31) 
Surf A 68/673 (10) Surf B 87/688 (13) 

Speer et al. [39] 
Prospective Randomized, multicenter, 7001500 g Treatment RDS on Vent, FIO_{2}>40% 
 Poractant (Surf A) (n=33, 1095 ± 226g, 28.9 ± 2.3wk)  Beractant (Surf B) (n=40, 1084 ± 252g, 28.8 ± 2.2wk) 
Poractant reduced FiO_{2} and ventilatory requirements for >24 hours, vs. Beractant group. 
Surf A 1/33 (3.0) Surf B 5/40 (12.5) 
Surf A 4/33 (12.5) Surf B 5/40 (11.4) 
Surf A 1/33 (3.0) Surf B 5/40 (12.5) 
Surf A 18/33 (54.6) Surf B 12/40 (30.0) 
Ramanathan et al. [42] 
Prospective Randomized, Multicenter, Double blind 7501750g, <35 wks, subgroup <32 wks 
 Poractant, 100mg/kg (Surf A) (n=96, 1145 ± 365g, 28.9 ± 2.0wk)  Poractant 200 mg/kg (Surf B) (n=99, 1151 ± 259g, 28.6 ± 2.0wk)  Beractant 100 mg/kg (Surf C) (n=98, 1187 ± 273g, 28.7 ± 2.0wk) 
Poractant 100 and 200 mg/kg initial dose reduced FiO_{2}, compared with Beractant group. Poractant 200 mg/kg intial dose had lower mortality vs. poractant 100 mg/kg or beractant groups. 
Subgroup <32 wks Surf A 9/85 (11) Surf B 3/95 (3) * Surf C 10/90 (11) 
Subgroup <32 wks Surf A 30/85 (35) Surf B 36/95 (38) Surf C 33/90 (37) 
Subgroup <32 wks Surf A 8/85 (9) Surf B 7/95 (7) Surf C 8/90 (9) 
Subgroup <32 wks Surf A 36/85 (42) Surf B 43/95 (45) Surf C 39/90 (43) 
Baroutis et al (2003)43 
Prospective Randomized 1 center, <32 wk, <2000 g , RDS on Vent 
 Alveofact (A), 100 mg/kg/dose (n=27, 1195 ± 390g, 29 ± 1.2wk)  Poractantvs(B),100 mg/kg/dose (n=27 1233 ± 380g, 28.7 ± 0.5wk)  Beractant (C) 100 mg/kg/dose (n=26, 1180 ± 410g, 29.2 ± 1wk) (Nonstandard dosing regimen) 
Alveofact and Poractant groups: spent fewer days on ventilator, fewer days on O_{2}, and spent fewer days in hospital than Beractant group. 
Surf A 7/27 (26) Surf B 5/27 (19) Surf C 6/26 (23) 
Surf A 3/27 (11) Surf B 4/27 (15) Surf C 4/26 (15) 
Surf A 5/27 (19) Surf B 6/27 (22) Surf C 4/26 (15) 
Surf A 5/27 (19) Surf B 4/27 (15) Surf C 5/26 (19) 
Malloy et al. [44] 
Prospective Randomized Open Label, 1 center, RDS, Vent, <37 wk 
 Poractant (Surf A) (n=29, 1394 ± 699g, 29.6 ± 3.6wk)  Beractant (Surf B) (n=29, 1408 ± 534g, 29.3 ± 2.9wk) 
Poractant decreased FiO_{2} in the first 2 days and a fewer PDA's than in Beractant.group. 
Surf A 0/29 (0) Surf B 3/29 (10) 
Surf A 10/29 (34) Surf B 10/26 (37) 
Surf A 4/28 (14) Surf B 6/21 (21) 
Surf A 5/29 (17) Surf B 13/29 (45)* 
Fujii et al. [45] 
Prospective Randomized Open Label
2 centers
RDS, Vent,
<30 wk 
 Poractant (Surf A) (n=25, 930 ± 231g, 27.1 ± 1.6wk)  Beractant (Surf B) (n=27, 900 ± 271g, 26.7 ± 1.7wk) 
Poractant decreased Mean Airway Pressures for 3 days, increased extubations at 23 days, and fewer PDA's than in Beractant group. 
Surf A 2/25 (8) Surf B 5/27 (19) 
Surf A 8/23 (35) Surf B 11/22 (50) 
Surf A 1/25 (4) Surf B 1/27 (4) 
Surf A 8/25 (32) Surf B 19/25 (76)* 
Sinha et al. [44] 
Prospective Randomized multicenter, double blind, prophylaxis noninferiority 2428 wk, 6001250 g 
 Lucinactant (Surf A) (n=119, 929 ± 189g, 27.0 ± 1.2wk)  Poractant (Surf B) (n=124, 937 ± 196g, 27.1 ± 1.4wk) (Nonstandard dosing regimen) 
Lucinactant and Poractant were similar in efficacy and safety when used for the prevention and treatment of RDS. 
Surf A 19/119 (16) Surf B 23/124 (19) 
Surf A 23/100 (23) Surf B 18/101 (18) 
Surf A 46/119 (39) Surf B 47/124 (37) 
Surf A 51/119 (43) Surf B 54/124 (44) 
Moya et al. [50] 
Randomized multicenter, double blind, RDS on Vent, <32 wk, 6001250 g 
 Lucinactant (Surf A) (n=527, 974 ± 183g, 28.2 ± 1.9wk)  Colfosceril (Surf B) (n=509, 971 ± 186g, 28.2 ± 2.0wk)  Beractant (Surf C) (n=258 997 ± 187g, 28.1 ± 2.1wk) (Nonstandard dosing regimen) 
Lucinactant more effective for RDS and BPD prevention than Colfosceril palmitate and decreased RDS mortality rates compared Beractant group. 
Surf A 111/527 (21) Surf B 124/509 (24) Surf C 68/258 (26)* 
BPD in all Enrolled Surf A 212/527 (40) Surf B 229/509 (45)* Surf C 109/258 (42) BPD in Survivors Surf A 212/416 (51) Surf B 229/385 (59)* Surf C 109/190 (57) 
Severe IVH/ PVL SurfA 115/527(22) SurfB 112/509(22) Surf C 55/258 (21) 
Surf A 195/527 (37) Surf B 188/509 (37) Surf C 95/258 (37) 
Dizdar et al. [51] 
Randomized multicenter, RDS on Vent, <37 wk 
 Poractant (Surf A) (n=61, 1165 g (6202290), 28 wk (2536)
 Beractant (Surf B) (n=65, 1080 g (5102750) , 28 wk (2836) 
Poractant decreased multiple doses, increased early extubation, decreased, FIO_{2}, and decreased BPD compared with beractant. 
Surf A 6/61 (10) Surf B 13/65 (20) 
BPD in all Enrolled Surf A 38/61 (58)
Surf B 48/65 (79)* 
Surf A 13/61 (22)
Surf B 9/65 (14) 
Surf A 33/65 (55)
Surf B 46/61 (71) 